Astria Therapeutics, Inc. (ATXS)
- Previous Close
3.9000 - Open
4.2700 - Bid 3.8800 x 100
- Ask 3.9900 x 100
- Day's Range
3.6914 - 4.3300 - 52 Week Range
3.5550 - 12.9200 - Volume
288,840 - Avg. Volume
389,575 - Market Cap (intraday)
222.633M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-1.6800 - Earnings Date Aug 11, 2025 - Aug 15, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
28.67
Astria Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is navenibart, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in clinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts.
www.astriatx.comRecent News: ATXS
View More
Performance Overview: ATXS
Trailing total returns as of 5/14/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ATXS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ATXS
View MoreValuation Measures
Market Cap
220.09M
Enterprise Value
-7.36M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.98
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-22.56%
Return on Equity (ttm)
-32.89%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-108.04M
Diluted EPS (ttm)
-1.6800
Balance Sheet and Cash Flow
Total Cash (mrq)
295.06M
Total Debt/Equity (mrq)
1.75%
Levered Free Cash Flow (ttm)
-63.19M